pre-seed
Stage
1
Investors
About
STANT B.V. develops proprietary inhibitors of the STING pathway aimed at novel therapeutics for autoimmune, inflammatory, cardiovascular, metabolic, and neurodegenerative diseases.
Explore STANT B.V's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.